Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: J Immunol. 2015 Jun 15;195(2):621–631. doi: 10.4049/jimmunol.1401823

Figure 1. SialoL impairs mast cell-derived production of IL-9 without affecting degranulation, IL-6 secretion and cell viability.

Figure 1

Mast cells were stimulated with ionomycin (Iono, 1μM) in the presence or absence of different concentrations of sialoL (1.5, 3 and 6.0μM). Production of IL-9 was determined by intracellular flow cytometry (A, B), and ELISA (C) after 48h of stimulation. IL-6 production was measured by ELISA after 24h of stimulation (D). Degranulation of mast cells was assessed after sensitization with IgE and crosslinking with the aid of anti-IgE as described in the materials and methods section (E). Cell viability was measured via FACS using “Fixable Viability Dye” (eBioscience) (F). Except for panel (A) (one representative from three independent experiments) the mean of three independent experiments (±SD) is shown. * P≤0.05; **≤P 0.01; ***≤P 0.001 (two- tailed unpaired t-test). ns= not significant.